150 related articles for article (PubMed ID: 17375384)
1. Managing conflicts of interest: a survival guide for biotechs.
Werner MJ; Price E
Nat Biotechnol; 2007 Feb; 25(2):161-3. PubMed ID: 17375384
[TBL] [Abstract][Full Text] [Related]
2. Ejecting the FDA from the courtroom.
Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
[No Abstract] [Full Text] [Related]
3. Bilski blundering biotech.
Simmons WJ
Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
[No Abstract] [Full Text] [Related]
4. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
5. Medical devices on trial, Part I.
Wright D
Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529
[TBL] [Abstract][Full Text] [Related]
6. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
[No Abstract] [Full Text] [Related]
8. Report: FDA exerts too little oversight of researchers' conflicts of interest.
Kuehn BM
JAMA; 2009 Feb; 301(7):709-10. PubMed ID: 19224741
[No Abstract] [Full Text] [Related]
9. Moving goalposts--regulatory oversight of antibacterial drugs.
Brenner R; Ellis-Grosse EJ; Echols R
Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
[TBL] [Abstract][Full Text] [Related]
10. More regulation of industry-supported biomedical research: are we asking the right questions?
Fry-Revere S; Malmstrom DB
J Law Med Ethics; 2009; 37(3):420-30, 395. PubMed ID: 19723253
[TBL] [Abstract][Full Text] [Related]
11. Financial disclosure by clinical investigators; correction--FDA. Final rule; correction.
Fed Regist; 1998 Jun; 63(124):35134. PubMed ID: 10180634
[TBL] [Abstract][Full Text] [Related]
12. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
13. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
14. [Medical devices approval process, a new French exception?].
Braillon A
Presse Med; 2011 Apr; 40(4 Pt 1):446-7. PubMed ID: 21334845
[No Abstract] [Full Text] [Related]
15. Better regulation of industry-sponsored clinical trials is long overdue.
Wynia M; Boren D
J Law Med Ethics; 2009; 37(3):410-9, 395. PubMed ID: 19723252
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany].
Vollmar HC; Georgieff P; Bührlen B
Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):738-43. PubMed ID: 21147437
[TBL] [Abstract][Full Text] [Related]
17. Physicians and clinical trials. To avoid federal scrutiny, take care when determining fair market value.
Morillo A
Mod Healthc; 2013 Sep; 43(38):22. PubMed ID: 24340738
[No Abstract] [Full Text] [Related]
18. FDA reform plan edges closer to realisation.
Marx V
Lancet; 2012 Jun; 379(9832):2135. PubMed ID: 22690392
[No Abstract] [Full Text] [Related]
19. EU directive on clinical trials penalizes small sponsors.
Meldolesi A
Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
[No Abstract] [Full Text] [Related]
20. Managing surgical conflicts of interest.
Collier R
CMAJ; 2016 Oct; 188(15):1069. PubMed ID: 27620635
[No Abstract] [Full Text] [Related]
[Next] [New Search]
